Wordt geladen...
A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells
Treatment of HER2+ breast cancer with trastuzumab is effective and combination anti-HER2 therapies have demonstrated benefit over monotherapy in the neoadjuvant and metastatic settings. This study investigated the therapeutic potential of targeting the BAG-1 protein co-chaperone in trastuzumab-respo...
Bewaard in:
| Gepubliceerd in: | Oncotarget |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Impact Journals LLC
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4951334/ https://ncbi.nlm.nih.gov/pubmed/26958811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7944 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|